跳到正文
原文
Nature Medicine· Khaled Ezzedine·· 18 天前精选AI 评分85

Povorcitinib用于非节段性白癜风的两项III期临床试验结果

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

AI 导读

两项III期临床试验结果显示,povorcitinib 30 mg每日一次治疗非节段性白癜风的患者在面部和全身色素恢复方面显著优于安慰剂,且耐受性良好。

推荐理由

研究显示povorcitinib在治疗非节段性白癜风方面具有显著疗效和良好的耐受性,为该疾病提供了新的治疗选择。

正文

Abstract

There is an unmet need for repigmentation therapies for patients with nonsegmental vitiligo (NSV) who are candidates for systemic therapy. Here, 52-week primary results are reported from two parallel phase 3, randomized, double-blind, placebo-controlled trials of once-daily povorcitinib (oral, highly selective JAK1 inhibitor) 30 mg in adults with moderate-to-severe NSV (STOP-V1 and STOP-V2). STOP-V1 and STOP-V2 enrolled 467 and 449 patients, respectively. In both studies, the primary endpoint of ≥75% improvement in the facial Vitiligo Area Scoring Index (F-VASI75) at week 52 was met, demonstrating statistically significant and clinically meaningful repigmentation with povorcitinib versus placebo (STOP-V1: 18.9% versus 6.8%; odds ratio, 3.1; 95% confidence interval 1.6–5.9; P = 0.0003; STOP-V2: 18.9% versus 3.1%; odds ratio, 7.5; 95% confidence interval 3.0–18.6; P < 0.0001). Povorcitinib was well tolerated; the percentage of patients with any treatment-emergent adverse event (TEAE) was similar between the povorcitinib and placebo groups in both studies (STOP-V1/STOP-V2, 68.7%/66.7% versus 63.7%/62.7%). The most common TEAEs with povorcitinib were nasopharyngitis (STOP-V1/STOP-V2, 11.2%/11.3% versus placebo, 9.8%/11.1%), acne (10.7%/10.8% versus 3.0%/2.2%) and upper respiratory tract infection (6.9%/14.0% versus 9.0%/10.7%). Serious TEAEs were generally single events, and Janus kinase inhibitor class-specific TEAEs were absent or rare. These results support once-daily povorcitinib as an effective and well-tolerated systemic treatment for adults with moderate-to-severe NSV. ClinicalTrials.gov identifiers: NCT06113445, NCT06113471.

Main

Vitiligo is a chronic, autoimmune disease characterized by skin depigmentation resulting from the loss of melanocytes1,2. The global prevalence of diagnosed vitiligo is approximately 0.4%, with rates varying geographically and by age group3,4. Patients with segmental (unilateral distribution) and nonsegmental vitiligo (NSV; bilateral distribution) have distinct clinical characteristics and disease courses; NSV accounts for up to 90% of vitiligo cases5. Segmental vitiligo affects less body surface area (BSA) and responds best to treatment within 2 years of onset, after which other modalities (for example, surgery) may be considered6. Thus, large, controlled trials generally focus on NSV. Vitiligo is associated with other autoimmune conditions, such as thyroid disorders and type 1 diabetes7; psychosocial comorbidities, including depression, anxiety, suicidality and stigmatization8; and an overall reduction in quality of life9,10. Psychosocial and quality-of-life burden are further impacted by increased disease extent and/or visibility of lesions (for example, facial or hand involvement) and are greater in patients with darker skin types9,10,11. The 2026 INTERCEPT study consensus defines vitiligo severity beyond disease extent, including factors of disease activity, lesion visibility and psychosocial burden, among others, as determinants for recommending systemic therapy12.

The JAK–STAT signaling pathway has a critical role in the pathophysiology of vitiligo13. Activation of the JAK–STAT pathway leads to the production of CXCL10, which promotes further recruitment of cytotoxic CD8+ T cells responsible for the destruction of melanocytes14,15,16. Ruxolitinib (selective JAK1 and JAK2 inhibitor) cream was the first treatment approved for the repigmentation of NSV17 in several geographic regions, including the USA, Canada, the European Union and the UK. Ruxolitinib cream is indicated in patients aged ≥12 years for twice-daily topical treatment of affected areas up to 10% BSA18,19,20,21.

There is a need for effective and well-tolerated therapies for patients with NSV who are candidates for systemic therapy (that is, moderate-to-severe NSV12). Povorcitinib is an oral, highly selective JAK1 inhibitor22 currently being evaluated as a potential treatment for autoimmune and inflammatory diseases, including vitiligo. In a phase 2, randomized, dose-ranging study in adults with extensive NSV (≥8% affected BSA), povorcitinib was well tolerated and significantly improved facial and total body repigmentation with 15, 45 and 75 mg once-daily (QD) dosing versus placebo at 6 months, with 27.7%, 36.4% and 29.4% improvement from baseline in facial Vitiligo Area Scoring Index (F-VASI) respectively, versus 5.1% for placebo, and 19.1%, 17.8% and 15.7% improvement in total VASI (T-VASI) versus −2.3% for placebo23. Further repigmentation was observed with continued treatment over a period of 1 year. Because no clear dose–response for efficacy was observed in phase 2, the dose for the phase 3 studies was selected based on exposure–response modeling24 to optimize the long-term risk/benefit profile, which is particularly important for use in a chronic autoimmune condition such as vitiligo. Povorcitinib 30 mg QD was predicted to have more favorable efficacy and biomarker profiles versus 15 mg QD, and to have similar efficacy and biomarker profiles with a more favorable safety profile versus 45 and 75 mg QD24. Further, clinical, pharmacokinetic and pharmacodynamic data suggested that QD povorcitinib would provide an effective and durable response while avoiding JAK2-mediated pathways that have been associated with cytopenias22,25.

Here the 52-week primary results are reported from two identically designed phase 3, randomized, double-blind, placebo-controlled trials—Selective Treatment of Oral Povorcitinib in Vitiligo (STOP-V1 (NCT06113445) and STOP-V2 (NCT06113471))—evaluating the efficacy and safety of povorcitinib 30 mg QD in adults with moderate-to-severe NSV.

Results

Study overview

In STOP-V1 and STOP-V2, eligible patients aged ≥18 years with NSV, affected facial BSA (F-BSA) ≥0.5% and total BSA (T-BSA) ≥5% (no upper limit) were randomized 1:1 to receive oral povorcitinib 30 mg or placebo QD for a 52-week double-blind, placebo-controlled period followed by a 52-week open-label extension period during which all patients received povorcitinib 30 mg QD (Extended Data Fig. 1). The primary endpoint of the STOP-V studies was the proportion of patients achieving ≥75% improvement from baseline in F-VASI (F-VASI75) at week 52. Key secondary endpoints were the proportion of patients achieving a facial Vitiligo Noticeability Scale (VNS) score of 4 (a lot less noticeable) or 5 (no longer noticeable) at week 52; the proportion of patients achieving ≥50% or ≥75% improvement from baseline in T-VASI (T-VASI50 or T-VASI75) at week 52; and the percentage change from baseline in T-VASI at week 52. Other secondary efficacy endpoints were achievement of ≥50% or ≥90% improvement from baseline in F-VASI (F-VASI50 or F-VASI90), ≥90% improvement from baseline in T-VASI (T-VASI90), Facial Static Investigator Global Assessment (FsIGA) and Static Investigator Global Assessment (sIGA) of 0 (clear) or 1 (almost clear), and facial and total Patient Global Impression of Change-Vitiligo (F-PaGIC-V and T-PaGIC-V, respectively) of ‘very much improved’ or ‘much improved’ at week 52; the proportion of patients in each category of the FsIGA, sIGA, F-PaGIC-V, T-PaGIC-V and facial color-matching question (patient rating of facial color match between treated vitiligo skin and normal skin) at week 52; and the change from baseline in Vitiligo-Specific Quality of Life (VitiQoL) and Hospital Anxiety and Depression Scale (HADS) at week 52. Safety and tolerability were additional secondary endpoints. The percentage change from baseline in F-VASI was assessed as an exploratory endpoint. The proportion of patients with no increase in T-VASI and the proportion of patients with no new or expanding lesions were assessed in post hoc analyses.

Patients

A total of 916 adults were enrolled in the STOP-V trials (Fig. 1). In STOP-V1, 467 patients from 81 sites in Belgium, Canada, France, Germany, Japan, Mexico, the Netherlands, Poland, Spain and the USA were randomized to povorcitinib 30 mg (n = 233) or placebo (n = 234) between 29 November 2023 and 26 February 2025; the 52-week placebo-controlled period concluded on 24 February 2026 and the 52-week open-label extension period is ongoing. In STOP-V2, 449 patients from 68 sites in Bulgaria, Canada, France, Germany, Hungary, Italy, Poland, the UK and the USA were randomized to receive povorcitinib 30 mg (n = 223) or placebo (n = 226) between 27 November 2023 and 18 March 2025; the 52-week placebo-controlled period concluded on 17 March 2026 and the 52-week open-label extension period is ongoing. In STOP-V2, two patients (one in each treatment group) did not receive the study drug and were not included in the safety population. Overall, 82.2% and 82.9% of patients in STOP-V1 and STOP-V2 respectively, completed treatment during the 52-week placebo-controlled period. Discontinuation rates were similar between treatment groups in both studies, with withdrawal by patient being the most common reason for discontinuation (Fig. 1).

Fig. 1: Patient disposition.

aScreen failures were permitted to rescreen once at investigator discretion; 14 patients in STOP-V1 and 8 patients in STOP-V2 were randomized after rescreening. bOne patient did not receive ≥1 dose of study drug. cIndicates the primary reason for discontinuation.

Patient demographics and baseline clinical characteristics were generally similar across treatment groups and studies (Table 1). Median (range) age was 48.0 (18–89) years in STOP-V1 and 46.0 (18–79) years in STOP-V2. The majority of patients were female (STOP-V1, 55.0%; STOP-V2, 57.0%) and white (STOP-V1, 79.4%; STOP-V2, 84.9%). Patients with all Fitzpatrick skin types were included in both studies; 23.1% and 27.4% of patients in STOP-V1 and STOP-V2 respectively, had skin types IV to VI. Per inclusion criteria, all patients had facial vitiligo. In both studies, >94% of patients had vitiligo present on the trunk, lower extremities, upper extremities and hands; >85% had vitiligo on the head and/or neck (excluding face) and feet. A substantial proportion of patients also had vitiligo on the genitals (STOP-V1, 68.1%; STOP-V2, 72.2%). Patients in STOP-V2 had slightly more widespread disease than those in STOP-V1, as indicated by higher baseline mean F-VASI and T-VASI (1.17 and 23.0 respectively, versus 1.05 and 19.5). Patients in STOP-V2 also had longer disease duration than those in STOP-V1 (median (range), 18.3 (0.1–59.3) years versus 16.2 (0.1–61.9) years); across studies, most patients had vitiligo for >10 years (STOP-V1, 68.5%; STOP-V2, 71.5%) and had stable disease at baseline (STOP-V1, 61.2%; STOP-V2, 70.6%) per investigator assessment of the physical signs of disease activity. Approximately 40% of patients in both studies had received prior medications for vitiligo. Of selected comorbidities, the most common was thyroid disorder, affecting approximately 15% of patients in each study.

Table 1 Patient demographics and baseline disease characteristics

Full size table

Primary and key secondary efficacy endpoints

The primary endpoint of F-VASI75 at week 52 was attained by a significantly greater proportion of patients who received povorcitinib versus placebo in both STOP-V1 (modified nonresponder imputation (mNRI), 18.9% versus 6.8%; odds ratio (OR) 3.1; 95% confidence interval (CI) 1.6–5.9; P = 0.0003) and STOP-V2 (mNRI, 18.9% versus 3.1%; OR 7.5; 95% CI 3.0–18.6; P < 0.0001). Observed F-VASI75 response rates continued to increase without plateau to week 52 in both studies (Fig. 2a).

Fig. 2: Achievement of F-VASI75 and VNS 4 or 5 in STOP-V1 and STOP-V2.

a,b, Percentage of patients achieving F-VASI75 (a) and VNS 4 or 5 (b) at each visit are presented as observed, with error bars representing the 95% CI and n indicating the number of patients with available data at each time point. ***P < 0.001 or ****P < 0.0001 for povorcitinib versus placebo at week 52 using the Cochran–Mantel–Haenszel test with stratification by randomization factors. The overall family-wise type I error was controlled at a two-sided α of 0.05. A gatekeeping approach was applied to adjust for multiplicity. Patients with missing data at week 52 were imputed using mNRI for F-VASI75 (STOP-V1, 18.9% versus 6.8% (n = 233 versus n = 234), P = 0.0003; STOP-V2, 18.9% versus 3.1% (n = 223 versus n = 226), P < 0.0001), and VNS 4 or 5 (STOP-V1, 15.1% versus 3.2% (n = 233 versus n = 234), P < 0.0001; STOP-V2, 10.2% versus 1.6% (n = 223 versus n = 226), P = 0.0002).

The key secondary endpoint of facial VNS 4 or 5 at week 52 was self-reported by a significantly higher proportion of patients who received povorcitinib versus placebo in STOP-V1 (mNRI, 15.1% versus 3.2%; OR 5.2; 95% CI 2.2–12.5; P < 0.0001) and STOP-V2 (mNRI, 10.2% versus 1.6%; OR 7.5; 95% CI 2.2–25.6; P = 0.0002). Improved VNS 4 or 5 response rates were observed with povorcitinib versus placebo by the first assessment at week 24 in both studies (Fig. 2b).

For total body repigmentation, a higher proportion of patients achieved T-VASI50 at week 52 with povorcitinib versus placebo in STOP-V1 (mNRI, 18.4% versus 6.5%; OR 3.2; 95% CI 1.7–6.2; P = 0.0003) and STOP-V2 (mNRI, 12.9% versus 4.8%; OR 2.9; 95% CI 1.3–6.4; P = 0.0048). In both studies, observed T-VASI50 response rates increased with povorcitinib versus placebo from week 24 onward (Fig. 3a). For T-VASI75 at week 52, response rates were low in both studies. In STOP-V1, T-VASI75 response rates did not differ significantly between povorcitinib and placebo (mNRI, 2.6% versus 1.3%; OR 2.0; 95% CI 0.5–8.2; P = 0.3503); in STOP-V2, a significantly greater proportion of patients achieved T-VASI75 at week 52 with povorcitinib versus placebo (mNRI, 2.3% versus 0%; OR not evaluable owing to the absence of placebo responders; 95% CI not evaluable; P = 0.0393). Observed T-VASI75 response rates increased with povorcitinib versus placebo to week 52 in both studies (Fig. 3b).

Fig. 3: Achievement of T-VASI50 and T-VASI75, and percentage change from baseline in T-VASI in STOP-V1 and STOP-V2.

a,b, Percentage of patients achieving T-VASI50 (a) and T-VASI75 (b). *P < 0.05, **P < 0.01 or ***P < 0.001 for povorcitinib versus placebo at week 52 using the Cochran–Mantel–Haenszel test with stratification by randomization factors. The overall family-wise type I error was controlled at a two-sided α of 0.05. A gatekeeping approach was applied to adjust for multiplicity. Patients with missing data at week 52 were imputed using mNRI for T-VASI50 (STOP-V1, 18.4% versus 6.5% (n = 233 versus n = 234), P = 0.0003; STOP-V2, 12.9% versus 4.8% (n = 223 versus n = 226), P = 0.0048) and T-VASI75 (STOP-V1, 2.6% versus 1.3% (n = 233 versus n = 234), P = 0.3503; STOP-V2, 2.3% versus 0% (n = 223 versus n = 226), P = 0.0393). c, Mean change in T-VASI from baseline at each visit as observed. Baseline mean (95% CI) T-VASI for the povorcitinib and placebo groups was 19.5 (17.5–21.5) and 19.5 (17.5–21.4) respectively, in STOP-V1, and 23.1 (20.6–25.5) and 23.0 (20.5–25.6) in STOP-V2. ****P < 0.0001 for the LSM difference between povorcitinib versus placebo at week 52 using an analysis of covariance model with stratification by randomization factors. The overall family-wise type I error was controlled at a two-sided α of 0.05. A gatekeeping approach was applied to adjust for multiplicity. Patients who initiated prohibited therapy with a potential impact on vitiligo outcomes before week 52 were imputed using the baseline T-VASI score. Patients with missing data at week 52 were imputed using multiple imputation (STOP-V1, −24.1% versus −5.7% (n = 233 versus n = 234), P < 0.0001; STOP-V2, −21.1% versus −4.4% (n = 223 versus n = 226), P < 0.0001). Error bars represent the 95% CI and n values are the number of patients with available data at each time point. NS, not significant.

Patients had a significantly greater least squares mean (LSM) percentage change from baseline (indicating improvement) in T-VASI at week 52 with povorcitinib versus placebo in STOP-V1 (multiple imputation, −24.1% versus −5.7%; LSM difference, −18.4; 95% CI −24.0 to −12.8; P < 0.0001) and STOP-V2 (multiple imputation, −21.1% versus −4.4%; LSM difference, −16.8; 95% CI −21.9 to −11.7; P < 0.0001). Separation between povorcitinib and placebo groups in the percentage change from baseline in T-VASI was observed by week 12 (second on-treatment visit) in both studies (Fig. 3c).

Other secondary efficacy endpoints

Patients who received povorcitinib versus placebo had greater response rates or improvements in nearly all investigator-assessed (F-VASI50 and F-VASI90 (Extended Data Fig. 2a,b) and FsIGA and sIGA), and patient-reported secondary outcomes (F-PaGIC-V, T-PaGIC-V, facial color-matching, VitiQoL) at week 52 (Extended Data Table 1). Few patients achieved T-VASI90 at week 52, and changes in HADS anxiety and depression scores were minimal.

Safety

TEAEs were generally consistent between studies (Table 2). In STOP-V1, 68.7% of patients in the povorcitinib group and 63.7% in the placebo group experienced any TEAE during the 52-week placebo-controlled period. In STOP-V2, 66.7% and 62.7% of patients respectively, experienced any TEAE. The most common TEAEs with povorcitinib (occurring in ≥5% of patients in either study) were nasopharyngitis (STOP-V1, 11.2%; STOP-V2, 11.3%), acne (STOP-V1, 10.7%; STOP-V2, 10.8%), upper respiratory tract infection (STOP-V1, 6.9%; STOP-V2, 14.0%), blood creatine phosphokinase (CPK) increase (STOP-V1, 6.9%; STOP-V2, 6.3%), headache (STOP-V1, 5.2%; STOP-V2, 6.8%), influenza (STOP-V1, 3.9%; STOP-V2, 5.0%), sinusitis (STOP-V1, 2.6%; STOP-V2, 5.0%) and hypercholesterolemia (STOP-V1, 0.9%; STOP-V2, 5.0%). Although CPK elevations were among the most common TEAEs, overall blood levels were similar to baseline in most patients (Extended Data Fig. 3). Treatment-related TEAEs occurred in 30.9% of patients in the povorcitinib group and in 21.4% of patients in the placebo group in STOP-V1, and in 33.3% and 18.7% of patients respectively, in STOP-V2. The most common TEAEs considered by investigators as related to povorcitinib treatment (occurring in >3% of patients in either study) were acne (STOP-V1, 10.3%; STOP-V2, 10.4%), headache (STOP-V1, 3.0%; STOP-V2, 4.1%), upper respiratory tract infection (STOP-V1, 1.7%; STOP-V2, 4.5%), blood CPK increase (STOP-V1, 2.1%; STOP-V2, 3.2%) and hypercholesterolemia (STOP-V1, 0.9%; STOP-V2, 4.1%).

Table 2 TEAEs during the 52-week placebo-controlled period

Full size table

Increased blood CPK was the most common grade ≥3 TEAE; none were considered serious. Most were asymptomatic and attributed to intense exercise or physical activity. The frequency of serious TEAEs was similar between treatment groups in both studies. Nearly all serious TEAEs were single events (Extended Data Table 2), with only one occurring in >1 patient in either study (urinary tract infection (n = 2) in the povorcitinib group in STOP-V1). Discontinuations owing to TEAEs were slightly higher with povorcitinib versus placebo in both studies. Only one TEAE led to discontinuation of povorcitinib in >1 patient in either study (blood CPK increased; n = 4 in STOP-V1 and n = 1 in STOP-V2; demographics consistent with the overall population); four of these events were attributed to intense physical training or work-related physical exertion and one was of unknown cause. Discontinuations due to increased CPK events were based on prespecified protocol stopping criteria (CPK >5 times the upper limit of normal (ULN) 3 weeks after the first elevated CPK event) rather than clinical symptoms.

The frequency of JAK inhibitor class-specific TEAEs (protocol-defined TEAEs of special interest) was generally similar between povorcitinib and placebo in both studies (STOP-V1, 3.0% versus 2.1%; STOP-V2, 2.3% versus 2.2%), and these events were rare (Table 2). There were no occurrences of major adverse cardiovascular event (MACE), tuberculosis or mortality. Nonmelanoma skin cancer (NMSC) or keratinocyte carcinoma occurred in four patients who received povorcitinib (basal cell carcinoma: STOP-V1, n = 1; STOP-V2, n = 3) and none who received placebo; all were grade 1 or 2 in severity and resolved during the study. Only one of these events (grade 2 left frontal basal cell carcinoma) was considered related to treatment and led to discontinuation; this patient (Fitzpatrick skin type II) had prior treatment with UVB phototherapy for 4 years and a topical calcineurin inhibitor for 7 years. One other patient with basal cell carcinoma during the study had previously received phototherapy and had a history of squamous cell carcinoma in situ and basal cell carcinoma (adequately treated and excised) before study enrollment. No other types of malignancy occurred in patients in the povorcitinib group in either study. One patient who received povorcitinib in STOP-V2 experienced pulmonary embolism (grade 3; serious; resolved), thrombosed varicose vein (grade 3; nonserious; resolved) and deep vein thrombosis (grade 3; nonserious; resolving); these events were considered related to povorcitinib treatment and povorcitinib was discontinued. The investigator considered an event of Mycoplasma pneumoniae infection (which persisted for >4 months and resolved 5 weeks before the pulmonary embolism) as a possible contributor to the pulmonary embolism; other risk factors included a history of varicose veins of the lower limbs, rheumatoid arthritis, hypertension and smoking. No other embolic or thrombotic events occurred in either study. Herpes zoster occurred in two patients in each treatment group in STOP-V1 and in one patient in the povorcitinib group in STOP-V2; all were grade 2, nonserious and resolved or were resolving. There were no occurrences of gastrointestinal perforation in patients who received povorcitinib. Hypersensitivity reactions occurred in two patients in each treatment group in STOP-V1 and in one patient in the placebo group in STOP-V2; all were grade 1 or 2, and none were considered related to treatment.

There were no clinically meaningful trends in liver (alanine aminotransferase, aspartate aminotransferase) (Extended Data Fig. 4a,b) or hematology parameters (hemoglobin, platelets) (Extended Data Fig. 5a,b) associated with povorcitinib and no indicators of drug-induced liver injury. No trends regarding weight gain were observed in either study.

Exploratory, sensitivity and post hoc analyses

Visible, progressive repigmentation of both facial (Fig. 4a,b) and body (Fig. 4c,d) lesions was observed in different patients who received povorcitinib. Continued improvement in the mean percentage change from baseline in F-VASI was observed with povorcitinib versus placebo to week 52 in both studies (STOP-V1, −36.8% versus −10.1%; STOP-V2, −36.4% versus −8.3%) (Extended Data Fig. 6), with separation between treatment groups observed from week 12 onward.

Fig. 4: Facial and body repigmentation in patients treated with povorcitinib.

a–d, Selected clinical images of facial repigmentation (a,b) and body repigmentation (c,d) in different patients treated with povorcitinib.

Sensitivity and supplementary analyses of the primary endpoint, including NRI, multiple imputation, longitudinal logistic regression and analysis of the per-protocol population, were consistent with the primary analysis in both studies (Extended Data Table 3). In addition, F-VASI75 response rates at week 52 were generally consistent across prespecified subgroups, including age, sex, race and baseline disease characteristics (Extended Data Fig. 7).

Post hoc analyses indicated increased disease stabilization with povorcitinib treatment. In both studies, a higher proportion of patients who received povorcitinib versus placebo had no increase in T-VASI (suggesting no worsening or progression of disease) at week 52 (STOP-V1, 94.3% versus 71.8%; STOP-V2, 87.6% versus 69.2%); comparable results were observed among patients with active disease at baseline (STOP-V1, 95.5% versus 73.4%; STOP-V2, 84.2% versus 66.7%). Similarly, more patients who received povorcitinib versus placebo had no new lesions and no expansion of existing lesions at week 52 in the overall study populations (STOP-V1, 94.2% versus 80.3%; STOP-V2, 84.2% versus 78.7%) and among patients with active disease at baseline (STOP-V1, 92.4% versus 79.7%; STOP-V2, 75.4% versus 72.5%).

Discussion

There is substantial unmet need for systemic repigmentation therapies among patients with moderate-to-severe vitiligo. The INTERCEPT consensus identified affected BSA as the starting point for assessment of vitiligo severity (mild, <3%; moderate, 3% to <10%; severe, ≥10%)12. Additional factors, including disease activity, involvement of highly visible areas (for example, the face and hands) and psychosocial burden (for example, stigmatization) may escalate patients from moderate to severe disease; rapidly progressing or spreading disease is considered severe regardless of BSA involvement12. Consistent with the INTERCEPT consensus, the STOP-V studies enrolled systemic-eligible adults with moderate-to-severe NSV.

In the STOP-V studies, povorcitinib 30 mg QD demonstrated statistically significant and clinically meaningful improvements versus placebo in facial and total body repigmentation over 52 weeks. The primary and key secondary endpoints of F-VASI75 and T-VASI50, both of which had significantly higher response rates with povorcitinib versus placebo, represent thresholds of meaningful change among both patients and clinicians26,27. F-VASI75 response rates were consistent across prespecified subgroups for demographics (for example, race and skin type) and baseline disease characteristics (for example, disease duration). In addition, the proportions of patients achieving facial VNS 4 or 5 with povorcitinib in each study were approaching the proportions achieving F-VASI75, indicating that patient-perceived improvements align with measured clinical improvements. There was a consistently higher placebo response rate across endpoints in STOP-V1 versus STOP-V2. Although the reason for this is unknown, patients in STOP-V2 having more extensive disease at baseline versus those in STOP-V1 may have contributed to a lower placebo response. In addition, assessment of depigmentation may be more difficult in patients with skin types I and II (STOP-V1, 42%; STOP-V2, 32%), and STOP-V1 included more study sites versus STOP-V2 (81 versus 68) with approximately the same number of total patients; both factors may contribute to overall variability. Discontinuation rates in the STOP-V studies were low (17–18%) and comparable between treatment groups despite 1-year placebo control without rescue for potentially worsening patients.

Repigmentation with povorcitinib increased to week 52 without evidence of plateau across efficacy endpoints, suggesting that further improvement may occur with continued treatment. This trajectory is consistent with the biology of repigmentation in vitiligo, which often requires prolonged, continuous treatment13,28. Accordingly, longer treatment duration is likely needed to achieve increased T-VASI75 response rates (a stringent threshold for repigmentation), which were low at week 52 in both studies. The use of UVB phototherapy in combination with povorcitinib may further improve or accelerate repigmentation, as previously demonstrated with other topical and oral JAK inhibitors29,30.

Patients enrolled in the STOP-V studies had extensive disease (mean baseline T-VASI ~20), most had long-standing disease (>10 years) and approximately one-third of patients in both studies had physical signs of active disease at baseline, including confetti pigmentation, Koebner phenomenon and trichrome appearance of vitiligo. Active disease is associated with increased psychosocial and quality-of-life burden8,10. In addition to repigmentation, disease stabilization may be a meaningful treatment goal for patients with active disease28,31. In both STOP-V studies, a higher proportion of patients who received povorcitinib versus placebo had no increase in T-VASI as well as no new lesions or expansion of existing lesions at week 52, suggesting a possible effect on disease progression. Between both studies, patients from three continents (North America, Europe and Asia) were included. Patients with all Fitzpatrick skin types were included in both studies, with most patients having skin types II, III or IV. In addition, a substantial proportion of patients in both studies had vitiligo affecting anatomic regions generally considered refractory to treatment, including the hands, feet and genitals.

Povorcitinib 30 mg QD was well tolerated, with no new safety signals identified; results were consistent with its known safety profile23,32,33. The overall rates of TEAEs were similar between povorcitinib and placebo treatment groups and across both studies (63–69%). The rates of serious TEAEs were low and similar between the povorcitinib and placebo groups. The most common grade ≥3 TEAE was increased blood CPK; none were serious, and most of these events were attributed to intense physical activity, consistent with an exertional rather than a drug-mediated mechanism. Dose-dependent increases in blood CPK are a recognized, generally asymptomatic effect of systemic JAK inhibition34,35,36 and are not typically associated with clinical events37. The lack of clinically meaningful trends in liver or hematology parameters associated with povorcitinib treatment supports its overall laboratory safety profile and may suggest that continuous laboratory monitoring is not needed. In addition, JAK inhibitor class-specific TEAEs were infrequent or absent, with no MACE, tuberculosis or mortality in either study. Basal cell carcinoma (an NMSC) occurred in four patients who received povorcitinib; all were grade 1 or 2 and resolved, and several patients had prior phototherapy or a history of skin cancer. NMSCs of mild or moderate severity have been reported in other vitiligo studies with topical or systemic JAK inhibitors38,39. Thromboembolic events occurred in a single patient with several established risk factors; this low incidence is consistent with the thromboembolic safety profile reported with other oral JAK inhibitors40.

Several other oral JAK inhibitors are currently being evaluated in patients with vitiligo38,41,42,43. Interferon-gamma signaling, a key mediator in vitiligo pathogenesis14, requires JAK1 and JAK2. Because JAK2 is essential for hematopoiesis44, selective targeting of JAK1 may reduce cytopenias associated with less-selective JAK inhibition. Povorcitinib demonstrated potent selectivity for JAK1 while sparing JAK2, had no activity against JAK3 and had negligible potency toward tyrosine kinase 222. At the highest povorcitinib clinical dose evaluated (75 mg QD), model-informed pharmacokinetic and pharmacodynamic analyses indicated sustained JAK1 inhibition with minimal JAK2 engagement25, supporting a wide margin between the therapeutic dose and doses at which JAK2-related safety concerns would be expected. Consistent with this JAK1-selective mechanism, povorcitinib 30 mg QD treatment resulted in no clinically meaningful changes in hematology parameters (hemoglobin, platelets) over 52 weeks in the STOP-V studies. The overall safety profile of povorcitinib was generally consistent with long-term data reported with oral JAK1 inhibitors in other dermatological conditions45. Weight gain, as has been noted with other oral JAK inhibitors45,46, was not observed in the STOP-V studies. Further analysis of weight gain in patients with vitiligo treated with oral JAK inhibitors may be warranted, because different inflammatory conditions could independently contribute to metabolic abnormalities.

The STOP-V studies were placebo-controlled without an active comparator, precluding direct comparisons with other therapies. Cross-trial comparisons are further limited by substantial differences in study populations, study design and other methodological factors (both disease-specific and independent). Additional limitations of the STOP-V studies include eligibility criteria that may not fully reflect a real-world comorbid population. Povorcitinib was assessed as a monotherapy, whereas many clinicians typically use combination therapy approaches in practice. Furthermore, the high percentage of white patients (80–85%) may limit generalizability to the global population. Study data are limited to the 52-week placebo-controlled period, and longer treatment duration is likely needed to fully assess the maximal treatment effect, because repigmentation is a slow process; however, the upward trend in repigmentation over 1 year is promising and consistent with other clinical trial data42,47,48. The 52-week open-label extension is ongoing and will provide additional long-term efficacy and safety data.

In summary, povorcitinib treatment provided clinically meaningful repigmentation for adult patients with NSV (per F-VASI75 and T-VASI50 outcomes) and showed continued improvement in efficacy outcomes over 1 year without plateau. The risk–benefit profile of povorcitinib 30 mg QD was favorable, with no new safety signals identified. These 52-week findings from the STOP-V studies demonstrate that povorcitinib is an effective and well-tolerated systemic treatment option for adults with moderate-to-severe NSV.

Methods

Patients and study design

The STOP-V studies were identically designed phase 3, randomized, double-blind, placebo-controlled trials (STOP-V1 and STOP-V2) evaluating the efficacy and safety of povorcitinib 30 mg in adults with NSV (Extended Data Fig. 1). These studies were conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines and any country-specific regulations. Study protocols were approved by the institutional review board or independent ethics committee as applicable at each site in each participating country, including Bulgaria: Ethics Committee for Clinical Trials (Sofia); Canada: Advarra Canada (Aurora, Ontario) and Health Canada (Ottawa, Ontario); France: Comité de Protection des Personnes (CPP; Île de France) and CPP Ouest I, Hôpital Bretonneau (Paris); Hungary: Medical Research Council Ethics Committee for Clinical Pharmacology (ECCP; Budapest); Italy: Comitato Etico Lombardia 4 – Fondazione IRCCS (Milan); Japan: St. Marianna University School of Medicine Hospitals (Kawasaki), Kobe University Hospital (Kobe), Dokkyo Medical University Saitama Medical Center (Koshigaya), University Hospital, Kyoto Prefectural University of Medicine (Kyoto), Tohoku University Hospital (Sendai), Nagasaki University Hospital (Nagasaki), Nagoya City University Hospital (Nagoya), Kochi Medical School Hospital (Nankoku), Niigata University Medical and Dental Hospital (Niigata), National Hospital Organization Okayama Medical Center (Okayama), the University of Osaka Hospital (Suita), Institute of Science Tokyo Hospital (Tokyo), NTT Medical Center Tokyo (Tokyo), Tokyo Medical University Hospital (Tokyo), Juntendo University Urayasu Hospital (Urayasu) and Yamagata University Hospital (Yamagata); Mexico: Comité de Ética Clinica GRAMEL SC (Mexico City); the Netherlands: Medical Ethics Review Committee (METC) Amsterdam UMC (Amsterdam); Poland: Supreme Bioethics Committee (Naczelna Komisja Bioetyczna, NKB; Warsaw); Spain: Comité de Ética de la Investigación con medicamentos (CEIm), Research Institute Hospital 12 de Octubre (Madrid); UK: North West – Greater Manchester Central Research Ethics Committee (London); and USA: Advarra (Columbia, MD). Ethics committees in Belgium and Germany were not disclosed. All patients provided written informed consent before enrollment. Participation in these studies was voluntary, and patients received no financial compensation. Study protocols and the statistical analysis plan are available in the Supplementary Information. Patients eligible for inclusion in the STOP-V studies were required to meet all of the following criteria:

  1. (1)

    Ability to comprehend and willingness to sign a written informed consent form for the study

  2. (2)

    Aged ≥18 years at the time of consent

  3. (3)

    Clinical diagnosis of NSV and meet the following at screening and baseline:

    1. (i)

      T-BSA ≥5%

    2. (ii)

      T-VASI ≥4

    3. (iii)

      F-BSA ≥0.5%

    4. (iv)

      F-VASI ≥0.5

    5. (v)

      Candidate for systemic therapy, as assessed by the investigator

    Note: Assessment of BSA and VASI must be performed using a Wood lamp in a darkened room

  4. (4)

    Agreement to discontinue all agents and procedures used to treat vitiligo from screening to the final safety follow-up visit

  5. (5)

    Willingness to avoid pregnancy or fathering children based on the criteria below

    1. (i)

      Male patients with reproductive potential must agree to take appropriate precautions to avoid fathering children from screening to 90 days (a spermatogenesis cycle) after the last dose of study drug and must refrain from donating sperm during this period. Permitted methods in preventing pregnancy should be communicated to the patients and their understanding confirmed

    2. (ii)

      Female patients who are women of childbearing potential must have a negative serum pregnancy test at screening and a negative urine pregnancy test before the first dose on day 1 and must agree to take appropriate precautions to avoid pregnancy from screening to 90 days after the last dose of study drug and must refrain from donating oocytes during this period. Permitted methods in preventing pregnancy should be communicated to the patients and their understanding confirmed

    3. (iii)

      Female patients not considered to be of childbearing potential are eligible

  6. (6)

    Willing and able to comply with the study protocol and procedures, including photography.

Patients were not eligible for inclusion in the STOP-V studies if they met any of the following exclusion criteria:

  1. (1)

    Other forms of vitiligo (for example, segmental) or other skin depigmentation disorders (for example, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma and tinea versicolor)

  2. (2)

    Clinically significant abnormal thyroid-stimulating hormone or free thyroxine at screening as determined by the investigator

  3. (3)

    Use of laser or light-based treatment (phototherapy), including tanning beds, within 8 weeks prior to day 1

  4. (4)

    Use of dihydroxyacetone (generally present in self-tanning products) within 4 weeks prior to day 1

  5. (5)

    Current or past use of the depigmenting agent monobenzyl ether of hydroquinone, including Benoquin (monobenzone)

  6. (6)

    History of melanocyte–keratinocyte transplantation procedure or other surgical treatment for vitiligo

  7. (7)

    Spontaneous and significant repigmentation within 6 months before screening (for example, repigmentation without any treatment and significant in amount as determined by the investigator)

  8. (8)

    Women who are pregnant, considering pregnancy or breastfeeding

  9. (9)

    Concurrent conditions or history of other diseases, as follows:

    1. (i)

      Thrombocytopenia, coagulopathy or platelet dysfunction

    2. (ii)

      Venous and arterial thrombosis, deep vein thrombosis, pulmonary embolism, stroke, moderate-to-severe heart failure (New York Heart Association Class III or IV), cerebrovascular accident, myocardial infarction, coronary stenting or coronary arterial revascularization with bypass graft surgery

    3. (iii)

      Diagnosis of other significant cardiovascular diseases, including but not limited to angina, peripheral arterial disease or uncontrolled arrhythmias such as atrial fibrillation, supraventricular tachycardia, ventricular tachycardia and forms of carditis

    4. (iv)

      Uncontrolled hypertension, as defined by a confirmed systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg

    5. (v)

      Patients who are bedridden or wheelchair assisted

    6. (vi)

      Recipient of an organ transplant

    7. (vii)

      Any malignancies or history of malignancies with the exception of adequately treated or excised nonmetastatic basal cell or squamous cell cancer of the skin

    8. (viii)

      Conditions that could interfere with drug absorption, including but not limited to short-bowel syndrome

    9. (ix)

      Chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (for example, bronchiectasis), recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremitting cystitis), fungal infection, prior prosthetic joint infection at any time, or open, draining or infected skin wounds or ulcers

    10. (x)

      Current or history of disseminated herpes zoster, or recurrent (>1 episode of) dermatomal herpes zoster

    11. (xi)

      Current or history of disseminated herpes simplex

    12. (xii)

      Active systemic infection or any active infection that, based on the investigator’s clinical assessment, makes the patient an unsuitable candidate for the study

    13. (xiii)

      Any clinically significant medical condition (other than vitiligo) or any other reason that the investigator determines would interfere with the patient’s participation in this study, would make the patient an unsuitable candidate to receive study drug or would put the patient at risk by participating in the study

    14. (xiv)

      Any clinically significant medical condition (other than vitiligo), as determined by the investigator, that is not adequately controlled with appropriate treatment or may interfere with the course, severity or assessments of vitiligo

    15. (xv)

      Albinism

  10. (10)

    A screening 12-lead electrocardiogram that demonstrates clinically significant abnormalities requiring treatment (for example, acute myocardial infarction, serious tachyarrhythmias or bradyarrhythmias) or that is indicative of serious underlying heart disease (for example, cardiomyopathy, major congenital heart disease, low voltage in all leads, Wolff–Parkinson–White syndrome) or QT interval corrected (QTc) >480 ms (>470 ms in the UK only) at screening

    Note: In the event that a single QTc is >480 ms (>470 ms in the UK only), the patient may enroll if the average QTc for the three consecutive electrocardiograms is ≤480 ms (≤470 ms in the UK only) or with approval from the medical monitor

  11. (11)

    Have undergone significant trauma or major surgery (per investigator’s assessment) within 30 days preceding the screening visit

  12. (12)

    History of clinically significant (per investigator’s judgment) drug or alcohol abuse within 6 months preceding the screening visit

  13. (13)

    History of treatment failure with any systemic or topical JAK inhibitor for vitiligo or any other inflammatory condition

  14. (14)

    Receipt of medical treatment or investigational drugs within the following interval prior to day 1:

    1. (i)

      <12 weeks or 5 half-lives (if known), whichever is longer, for any investigational or experimental treatments

    2. (ii)

      <12 weeks or 5 half-lives (if known), whichever is longer, for immunomodulating biologic drugs

    3. (iii)

      <4 weeks for systemic immunosuppressive or immunomodulating small-molecule drugs (for example, corticosteroids (oral or intravenous), avacopan, IRAK4 inhibitors, methotrexate, cyclosporine, dapsone, azathioprine)

      Note: Use of corticosteroid inhalers and intranasal sprays is allowed

      Note: Use of oral corticosteroids for nondermatological conditions (for example, asthma exacerbation, bronchitis) is allowed for no longer than 7 days if deemed acceptable by the investigator and the sponsor (or designee)

    4. (iv)

      <8 weeks for live vaccine or planning to receive live vaccine during the course of the study or within 8 weeks after the last dose of study drug

    5. (v)

      <4 weeks for any topical or systemic JAK inhibitor

    6. (vi)

      <1 week for any oral or topical phosphodiesterase 4 inhibitor (for example, apremilast, crisaborole)

    7. (vii)

      <2 weeks for any topical drug applied to vitiligo lesions

    8. (viii)

      <1 week or 5 half-lives (if known), whichever is longer, for strong systemic CYP3A4 inhibitors and strong and moderate systemic CYP3A4 inducers. Examples include but are not limited to the following: rifampicin or rifampin, ketoconazole, itraconazole, carbamazepine, ritonavir, St John’s wort, grapefruit or grapefruit juice, and Seville oranges

  15. (15)

    At the screening visit, any of the following laboratory abnormalities:

    1. (i)

      Platelets, <100 × 109 per liter

    2. (ii)

      Hemoglobin, <10 g per deciliter

    3. (iii)

      Absolute neutrophil count, <1.5 × 109 per liter

    4. (iv)

      Total white blood cell count (leukocyte count), <3.0 × 109 per liter

    5. (v)

      Absolute leukocyte count, <0.8 × 109 per liter

    6. (vi)

      Alanine aminotransferase, >2× ULN

    7. (vii)

      Aspartate aminotransferase, >2× ULN

    8. (viii)

      Total bilirubin, >1.5× ULN

      Note: Patients with clinical diagnosis of Gilbert syndrome may have a direct bilirubin measured and would be eligible provided the direct bilirubin is below the ULN

    9. (ix)

      Estimated glomerular filtration rate, <45 ml min−1 per 1.73 m2

      Note: Based on the simplified four-variable Modification of Diet in Renal Disease formula

  1. (16)

    Evidence of infection with Mycobacterium tuberculosis

  2. (17)

    Active human immunodeficiency virus (HIV) infection or AIDS. Active HIV is defined as a confirmed positive anti-HIV antibody test

  3. (18)

    Evidence of hepatitis B virus or hepatitis C virus active infection or risk of reactivation

  4. (19)

    Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class

  5. (20)

    Any condition, laboratory result or result of screening assessments that would, in the investigator’s and sponsor’s (or designee’s) judgment, interfere with full participation in the study, including administration of study drug and attending required study visits, pose a significant risk to the patient or interfere with interpretation of study data

  6. (21)

    The following patients are excluded in France: vulnerable populations according to article L.1121-6 of the French Public Health Code and adults under legal protection, or who are unable to express their consent per article L.1121-8 of the French Public Health Code, not affiliated to a social security per article L.1121-8-1 of the French Public Health Code

  7. (22)

    The following patients are excluded in the European Union: patients with increased risks of events associated with JAK inhibitors (specifically increased risk of major cardiovascular events (for example, >65 years of age and current or past longtime smokers) and venous thromboembolism) unless the benefit to risk profile is still favorable in the opinion of the investigator

  8. (23)

    Leukotrichia in >33% of the face surface area affected with vitiligo lesions or leukotrichia in >33% of the total body (including the face) surface area affected with vitiligo lesions as assessed at screening

  9. (24)

    Had ≥3 laser hair removal treatments of an area to be treated for vitiligo

  10. (25)

    Concurrent enrollment in another clinical study.

Prohibited medications and procedures during the study included any topical or systemic JAK or tyrosine kinase 2 inhibitor other than povorcitinib, any other investigational or experimental treatments, systemic immunosuppressive or immunomodulating biologic drugs, systemic immunosuppressive or immunomodulating small-molecule drugs, systemic or topical phosphodiesterase 4 inhibitors, other topical agents for vitiligo, phototherapy, tanning beds and dihydroxyacetone (generally present in self-tanning products). There were no restrictions on exposure to natural sunlight. Bland emollients, camouflage makeups and sunscreen agents were permitted, although patients were instructed not to apply these on the days of study visits to allow proper assessment of vitiligo lesions.

Self-reported information regarding sex (female or male) was collected at screening and is summarized in Table 1. Sex was included in prespecified subgroup analyses of the primary endpoint. No information was collected regarding gender.

Randomization

Patients were randomized 1:1 using an interactive response technology to receive oral povorcitinib 30 mg or placebo QD for 52 weeks. Randomization was stratified by F-VASI (<1.5 and ≥1.5), T-VASI (4–20 and >20) and Fitzpatrick skin type (I–II and III–VI). Patients, investigators and the study sponsor remained blinded to assigned treatments during the 52-week placebo-controlled period (reported here). Following this period, all patients received open-label povorcitinib 30 mg QD for an additional 52-week extension period (ongoing). The current analysis reports the 52-week primary results from both STOP-V studies.

Assessments

The primary endpoint of the STOP-V studies was the proportion of patients achieving ≥75% improvement from baseline in F-VASI (F-VASI75) at week 52. Key secondary endpoints were the proportion of patients achieving a facial VNS score of 4 (a lot less noticeable) or 5 (no longer noticeable) at week 52, the proportion of patients achieving ≥50% improvement from baseline in T-VASI (T-VASI50) at week 52, the proportion of patients achieving ≥75% improvement from baseline in T-VASI (T-VASI75) at week 52 and the percentage change from baseline in T-VASI at week 52. Other secondary efficacy endpoints were achievement of ≥50% improvement from baseline in F-VASI (F-VASI50), ≥90% improvement from baseline in F-VASI (F-VASI90), ≥90% improvement from baseline in T-VASI (T-VASI90), FsIGA and sIGA of 0 (clear) or 1 (almost clear), and F-PaGIC-V and T-PaGIC-V, respectively of ‘very much improved’ or ‘much improved’ at week 52; the proportion of patients in each category of the FsIGA, sIGA, F-PaGIC-V, T-PaGIC-V, and a color-matching question where patients rated color match between facial treated vitiligo skin and normal skin from 1 (excellent) to 5 (very poor) at week 52; and the change from baseline in VitiQoL and HADS at week 52. The percentage change from baseline in F-VASI was assessed as an exploratory endpoint. The proportion of patients with no increase in T-VASI and the proportion of patients with no new or expanding lesions were assessed in post hoc analyses. Safety and tolerability were assessed through the frequency and severity of TEAEs (coded by the Medical Dictionary for Regulatory Activities version 27.1 and the Common Terminology Criteria for Adverse Events version 5.0) and clinical laboratory parameters. TEAEs of special interest included MACE and thrombotic events, malignancy, serious infections (defined as any infection meeting the protocol-defined criteria for serious adverse events), opportunistic infections (including herpes zoster and tuberculosis), gastrointestinal perforations and hypersensitivity reactions.

The VASI is a composite measure of both affected BSA and degree of depigmentation on the face (F-VASI; range, 0–3) or total body (T-VASI; range, 0–100)49. F-BSA considers depigmented areas on the face, excluding the ears, lips, neck and scalp. T-BSA considers depigmented areas on all body regions, including the face, head and/or neck, upper extremities, hands, trunk, lower extremities and feet. The VNS is a patient-reported measure of vitiligo treatment success50. Patients assessed current vitiligo on their face using a mirror and reported noticeability compared to a baseline facial photograph on a scale from 1 (more noticeable) to 5 (no longer noticeable), with a score of 4 or 5 representing treatment success. The FsIGA and sIGA are global measures of vitiligo severity from 0 (clear) to 5 (severe) that incorporate location, distribution, size, depigmentation and signs of activity. The F-PaGIC-V and T-PaGIC-V are patient-reported assessments of vitiligo improvement from 1 (very much improved) to 7 (very much worse). For the facial color-matching question, patients were provided with a mirror and asked to rate the facial color match between treated vitiligo skin and normal skin from 1 (excellent) to 5 (very poor); patients were shown their baseline facial image for reference. The VitiQoL is a 15-item patient-reported quality-of-life assessment in which various aspects of the condition are rated on a 7-point scale from ‘not at all’ to ‘all of the time’51. The HADS is a 14-item questionnaire assessing anxiety and depression (7 questions each, scored from 0 to 3; higher scores indicate more severe anxiety and depression)52.

Statistical analyses

Based on results from the phase 2 dose-ranging study using nonresponder imputation (povorcitinib) and the linear extrapolation method (placebo), assumed F-VASI75 response rates for the povorcitinib 30 mg and placebo groups were 20% and 8%, respectively. Sample size calculations using the χ2square test (two-sided α = 0.05) and an assumed 30% dropout rate determined that approximately 444 patients per study would provide 95.6% power to detect a difference between povorcitinib 30 mg and placebo in the primary endpoint of F-VASI75. The assumed response rates for the key secondary endpoints were as follows: percentage change in T-VASI, −35% for povorcitinib 30 mg and −5% for placebo; T-VASI50, 15% and 5%; VNS 4 or 5, 12% and 4%; T-VASI75, 7% and 2%; the corresponding estimated powers for the key secondary endpoints were >99.9%, 94.2%, 87.7% and 72.1%, respectively. The intent-to-treat population, used for all efficacy analyses, included all randomized patients. The safety population included all patients who received ≥1 dose of study drug.

To support the robustness of the primary analysis, three sensitivity analyses (nonresponder imputation, multiple imputation, longitudinal logistic regression) and one supportive analysis (of the per-protocol population (all randomized patients considered to be sufficiently compliant with the protocol)) were also conducted.

Primary and key secondary endpoints were tested using a gatekeeping approach in a fixed sequence (F-VASI75, percentage change from baseline in T-VASI, T-VASI50, VNS 4 or 5, T-VASI75 (all at week 52)) to control the rate of overall family-wise type I error with a two-sided α of 0.05. Statistical significance for the primary and binary key secondary endpoints was assessed using the Cochran–Mantel–Haenszel test with stratification for F-VASI (<1.5 and ≥1.5), T-VASI (4–20 and >20) and Fitzpatrick skin type (I–II and III–VI). The common OR and corresponding 95% CI for the comparison between treatment groups are reported. The percentage change in T-VASI was analyzed using an analysis of covariance model with treatment group and stratification factors as the fixed factors, and baseline T-VASI as covariates. The LSM treatment difference, associated 95% CI and P value are reported.

Patients with missing data at week 52 for the primary endpoint and key secondary endpoints with binary outcomes were imputed using mNRI. The use of mNRI was expected to better represent actual response rates in comparison to NRI. Patients who initiated prohibited therapy with potential impact on vitiligo outcomes before week 52 were considered nonresponders for all subsequent visits after the date of the intercurrent event. Patients with missing data for any other reason were imputed using multiple imputation (fully conditional specification method with treatment group, stratification factors and baseline and postbaseline scores as predictors). For percentage change from baseline in T-VASI, patients who initiated prohibited therapy with potential impact on vitiligo outcomes before week 52 were imputed using the baseline T-VASI score. Patients with missing data at week 52 were imputed using multiple imputation; missing data were imputed similar to binary outcomes followed by an analysis using the analysis of covariance model with treatment group, stratification factors and corresponding baseline values as predictors. By-visit analyses and all other endpoints are reported as observed and summarized using descriptive statistics. SAS software (SAS Institute Inc.; v9.1 or later) was used for all statistical analyses.

Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability

Incyte Corporation (Wilmington, DE, USA) is committed to data sharing that advances science and medicine while protecting patient privacy. Qualified external scientific researchers may request anonymized datasets owned by Incyte for the purpose of conducting legitimate scientific research. Researchers may request anonymized datasets from any interventional study (except phase 1 studies) for which the product and indication have been approved on or after 1 January 2020 in at least one major market (for example, USA, European Union, Japan). Data will be available for request after the primary publication or 2 years after the study has ended. Information on Incyte’s clinical trial data sharing policy and instructions for submitting clinical trial data requests are available at https://www.incyte.com/Portals/0/Assets/Compliance%20and%20Transparency/clinical-trial-data-sharing.pdf?ver=2020-05-21-132838-960.

References

  1. Bergqvist, C. & Ezzedine, K. Vitiligo: a review. Dermatology 236, 571–592 (2020).

    Article  PubMed  Google Scholar 

  2. Ezzedine, K., Eleftheriadou, V., Whitton, M. & van Geel, N. Vitiligo. Lancet 386, 74–84 (2015).

    Article  PubMed  Google Scholar 

  3. Akl, J. et al. Estimating the burden of vitiligo: a systematic review and modelling study. Lancet Public Health 9, e386–e396 (2024).

    Article  PubMed  Google Scholar 

  4. Haulrig, M. B. et al. The global epidemiology of vitiligo: a systematic review and meta-analysis of the incidence and prevalence. J. Eur. Acad. Dermatol. Venereol. 3, 1410–1419 (2024).

    Google Scholar 

  5. Taieb, A. & Picardo, M. Clinical practice. Vitiligo. N. Engl. J. Med. 360, 160–169 (2009).

    CAS  PubMed  Google Scholar 

  6. Shen, N. et al. Segmental vitiligo: a distinct entity with unique pathogenesis and clinical implications. J. Invest. Dermatol. 146, 1501–1513 (2026).

    Article  CAS  PubMed  Google Scholar 

  7. Rios-Duarte, J. A., Sanchez-Zapata, M. J. & Silverberg, J. I. Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study. Arch. Dermatol. Res. 315, 2597–2603 (2023).

    Article  PubMed  Google Scholar 

  8. Ezzedine, K. et al. Psychosocial effects of vitiligo: a systematic literature review. Am. J. Clin. Dermatol. 22, 757–774 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  9. Bibeau, K. et al. Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study. JAMA Dermatol. 159, 1124–1128 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  10. Picardo, M. et al. The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes. J. Eur. Acad. Dermatol. Venereol. 36, 1507–1523 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bibeau, K. et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J. Eur. Acad. Dermatol. Venereol. 36, 1831–1844 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Eleftheriadou, V. et al. Definition of severity and relapse for vitiligo: an international consensus statement. JAMA Dermatol. 162, 515–524 (2026).

    Article  PubMed  Google Scholar 

  13. McElroy, J. et al. Understanding the mechanism of disease of vitiligo and the impact on clinical management. J. Dermatol. Physician Assist. 19, 28–35 (2025).

    Article  Google Scholar 

  14. Harris, J. E. et al. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-γ for autoreactive CD8+ T-cell accumulation in the skin. J. Invest. Dermatol. 132, 1869–1876 (2012).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Rashighi, M. et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci. Transl. Med. 6, 223ra223 (2014).

    Article  Google Scholar 

  16. Richmond, J. M. et al. Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease. J. Invest. Dermatol. 137, 350–358 (2017).

    Article  CAS  PubMed  Google Scholar 

  17. Seneschal, J. et al. Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force–part 2: specific treatment recommendations. J. Eur. Acad. Dermatol. Venereol. 37, 2185–2195 (2023).

    Article  PubMed  Google Scholar 

  18. Opzelura (ruxolitinib cream) (Incyte Biosciences Distribution B.V., 2026).

  19. Opzelura (ruxolitinib cream) (Incyte Biosciences UK Ltd, 2026).

  20. Opzelura (ruxolitinib cream) (Incyte Corporation, 2026).

  21. Opzelura (ruxolitinib cream) product monograph (Incyte Corporation and Innomar Strategies, 2025).

  22. Zhuo, J. et al. Discovery of the orally bioavailable isoform selective Janus kinase 1 (JAK1) compound povorcitinib (INCB054707) for the treatment of inflammatory and autoimmune diseases. J. Med. Chem. 69, 12830–12852 (2026).

    Article  CAS  PubMed  Google Scholar 

  23. Pandya, A. G. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib in patients with extensive vitiligo in a phase 2, randomized, double-blinded, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 93, 946–955 (2025).

    Article  CAS  PubMed  Google Scholar 

  24. Wojciechowski, J. et al. Application of exposure–response modeling to inform the phase 3 dose selection of povorcitinib in nonsegmental vitiligo. In 7th Vitiligo International Congress poster P.42 https://www.incytemi.com/document/Poster/VIC%202026_Wojciechowski_STOP-V%20Dose%20Selection.pdf (2026).

  25. Szeto, K., Wang, Y., Purohit, V., Wojciechowski, J. & Santos, L. L. Model-informed comparative pharmacokinetic and pharmacologic profiling highlight JAK1 selectivity of povorcitinib. In Population Approach Group Europe (PAGE) Meeting Poster I-083 https://www.incytemi.com/document/Poster/PAGE%202026_Szeto_Povo%20PK%20Modeling%20and%20Selectivity.pdf (2026).

  26. Kitchen, H. et al. Meaningful changes in what matters to individuals with vitiligo: content validity and meaningful change thresholds of the Vitiligo Area Scoring Index (VASI). Dermatol. Ther. (Heidelb.) 12, 1623–1637 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  27. Ezzedine, K. et al. Psychometric properties and meaningful change thresholds of the Vitiligo Area Scoring Index. JAMA Dermatol. 161, 39–46 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  28. Prajapati, V. H. et al. Canadian consensus guidelines for the management of vitiligo. Dermatol. Ther. (Heidelb.) 15, 1351–1369 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

  29. Phan, K., Phan, S., Shumack, S. & Gupta, M. Repigmentation in vitiligo using Janus kinase (JAK) inhibitors with phototherapy: systematic review and meta-analysis. J. Dermatolog. Treat. 33, 173–177 (2022).

    Article  CAS  PubMed  Google Scholar 

  30. Pandya, A. G. et al. Efficacy and safety of ruxolitinib cream combined with narrow-band UVB phototherapy for treatment of vitiligo. J. Invest. Dermatol. 146, 1867–1875 (2026).

    Article  CAS  PubMed  Google Scholar 

  31. Seneschal, J. & Boniface, K. Vitiligo: current therapies and future treatments. Dermatol. Pract. Concept. 13, e2023313S (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  32. Kirby, J. S. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 90, 521–529 (2024).

    Article  CAS  PubMed  Google Scholar 

  33. Porter, M. L. et al. Povorcitinib for hidradenitis suppurativa: the randomized, double-blind, placebo-controlled STOP-HS1 and STOP-HS2 phase 3 trials. Nat. Med. 32, 3071–3081 (2026).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bieber, T. et al. Pooled safety analysis of baricitinib in adult patients with atopic dermatitis from 8 randomized clinical trials. J. Eur. Acad. Dermatol. Venereol. 35, 476–485 (2021).

    Article  CAS  PubMed  Google Scholar 

  35. Sandborn, W. J. et al. Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials. Clin. Gastroenterol. Hepatol. 17, 1541–1550 (2019).

    Article  CAS  PubMed  Google Scholar 

  36. Burmester, G. R. et al. Safety profile of upadacitinib over 15 000 patient-years across rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and atopic dermatitis. RMD Open 9, e002735 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  37. Nash, P. et al. Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Ann. Rheum. Dis. 80, 71–87 (2021).

    Article  CAS  PubMed  Google Scholar 

  38. Ezzedine, K. et al. Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial. J. Am. Acad. Dermatol. 88, 395–403 (2023).

    Article  CAS  PubMed  Google Scholar 

  39. Ezzedine, K. et al. Incidence of nonmelanoma skin cancer in patients with vitiligo who applied ruxolitinib cream. J. Eur. Acad. Dermatol. Venereol. 39, e378–e380 (2024).

    PubMed  PubMed Central  Google Scholar 

  40. Ingrassia, J. P. et al. Cardiovascular and venous thromboembolic risk with JAK inhibitors in immune-mediated inflammatory skin diseases: a systematic review and meta-analysis. JAMA Dermatol. 160, 28–36 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  41. Huang, F. et al. Efficacy and safety of Janus kinase inhibitors in patients with vitiligo: a systematic review and meta-analysis. Clin. Pharmacol. Ther. 117, 659–669 (2025).

    Article  CAS  PubMed  Google Scholar 

  42. Passeron, T. et al. Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study. EClinicalMedicine 73, 102655 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  43. Passeron, T. et al. Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies. Lancet 408, 636–648 (2026).

    Article  CAS  PubMed  Google Scholar 

  44. Neubauer, H. et al. JAK2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell 93, 397–409 (1998).

    Article  CAS  PubMed  Google Scholar 

  45. Facheris, P. et al. JAK inhibitor safety in atopic dermatitis and alopecia areata: a 4.5-year real-world retrospective cohort study. Dermatol. Ther. (Heidelb.) 16, 4305–4324 (2026).

    Article  PubMed  PubMed Central  Google Scholar 

  46. Xiong, G. et al. Weight gain secondary to the use of oral Janus kinase inhibitors: a systematic review and meta-analysis. JAAD Int. 19, 1–9 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

  47. Rosmarin, D. et al. Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo. N. Engl. J. Med. 387, 1445–1455 (2022).

    Article  CAS  PubMed  Google Scholar 

  48. Harris, J. E. et al. Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study. Br. J. Dermatol. 194, 591–593 (2026).

    Article  PubMed  Google Scholar 

  49. Hamzavi, I. et al. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch. Dermatol. 140, 677–683 (2004).

    Article  PubMed  Google Scholar 

  50. Batchelor, J. M. et al. Validation of the Vitiligo Noticeability Scale: a patient-reported outcome measure of vitiligo treatment success. Br. J. Dermatol. 174, 386–394 (2016).

    Article  CAS  PubMed  Google Scholar 

  51. Lilly, E. et al. Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL). J. Am. Acad. Dermatol. 69, e11–e18 (2013).

    Article  PubMed  Google Scholar 

  52. Zigmond, A. S. & Snaith, R. P. The Hospital Anxiety and Depression Scale. Acta Psychiatr. Scand. 67, 361–370 (1983).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank the patients, investigators and site personnel who participated in this study. The foundational draft manuscript was written by Sorcero, Inc. (Washington, DC, USA) utilizing the Sorcero bespoke AI process (V1.0) and was funded by Incyte Corporation. Subsequent medical writing support was provided by J. Brandwein, PhD, from Citrus Health Group, Inc. (Chicago, IL, USA) and was funded by Incyte Corporation.

Funding

This study was funded by Incyte Corporation (Wilmington, DE, USA). The study sponsor was involved in the study design, data collection, data analysis, data interpretation, writing of the manuscript, and decision to publish, in collaboration with all the authors.

Author information

Authors and Affiliations

  1. Henri Mondor University Hospital and Epidemiology in Dermatology and Evaluation of Therapeutics (EpiDermE), Paris-Est Créteil University, Créteil, France

    Khaled Ezzedine

  2. Department of Dermatology and Skin Science, University of British Columbia and Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

    Harvey Lui

  3. Royal Wolverhampton NHS Trust, Wolverhampton, UK

    Viktoria Eleftheriadou

  4. Institute for Global Health and Wellbeing, School of Medicine, Keele University, Keele, UK

    Viktoria Eleftheriadou

  5. Walsall Healthcare NHS Trust, Walsall, UK

    Viktoria Eleftheriadou

  6. Innovative Dermatology, Plano, TX, USA

    Seemal R. Desai

  7. Department of Dermatology, The University of Texas Southwestern Medical Center, Dallas, TX, USA

    Seemal R. Desai

  8. Centre Hospitalier Universitaire de Nice, Université Côte d’Azur, Nice, France

    Thierry Passeron

  9. INSERM U1065, C3M, Université Côte d’Azur, Nice, France

    Thierry Passeron

  10. Centre de Recherche Dermatologique du Québec Métropolitain, Québec City, Quebec, Canada

    Julien Ringuet

  11. McGill University, Montreal, Quebec, Canada

    Julien Ringuet

  12. Department of Dermatology, Ghent University Hospital, Ghent, Belgium

    Nanja van Geel

  13. Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium

    Nanja van Geel

  14. Department of Dermatology, Amsterdam University Medical Center, Amsterdam, the Netherlands

    Albert Wolkerstorfer

  15. Division of Dermatology, University of Toronto, Toronto, Ontario, Canada

    Charles Lynde

  16. The Lynde Institute for Dermatology & Lynderm Research Inc., Markham, Ontario, Canada

    Charles Lynde

  17. Probity Medical Research Inc, Markham, Ontario, Canada

    Charles Lynde

  18. University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    Matthias Augustin

  19. Hospital Universitario Fundación Alcorcón, Madrid, Spain

    José Luis López-Estebaranz

  20. Vitiligo & Pigmentation Institute of Southern California, Los Angeles, CA, USA

    Pearl Grimes

  21. Indiana University School of Medicine, Indianapolis, IN, USA

    David Rosmarin

  22. Incyte Corporation, Wilmington, DE, USA

    Kurt Brown, Shaoceng Wei, Sunanda Karanam & Deanna Kornacki

  23. Palo Alto Foundation Medical Group, Sunnyvale, CA, USA

    Amit G. Pandya

Authors

  1. Khaled Ezzedine
  2. Harvey Lui
  3. Viktoria Eleftheriadou
  4. Seemal R. Desai
  5. Thierry Passeron
  6. Julien Ringuet
  7. Nanja van Geel
  8. Albert Wolkerstorfer
  9. Charles Lynde
  10. Matthias Augustin
  11. José Luis López-Estebaranz
  12. Pearl Grimes
  13. David Rosmarin
  14. Kurt Brown
  15. Shaoceng Wei
  16. Sunanda Karanam
  17. Deanna Kornacki
  18. Amit G. Pandya

Contributions

All authors contributed to study conception and design, data analysis and interpretation, and drafting and revision of the manuscript for important intellectual content. All authors had access to and verified all the included data in the study and had final responsibility for the decision to submit for publication. K.E., K.B., S.W., S.K., D.K. and A.G.P. have access to the raw study data.

Corresponding author

Correspondence to Khaled Ezzedine.

Ethics declarations

Competing interests

K.E. is a consultant for AbbVie, Incyte Corporation, La Roche-Posay, Pfizer, Pierre Fabre, Sanofi and Viela Bio. H.L. has served as an advisor, consultant, investigator and/or speaker for AbbVie, Incyte Corporation, L’Oréal, Pfizer and Vita Imaging. V.E. has served as a consultant, investigator and/or speaker for AbbVie, Almirall, Beiersdorf, Boehringer Ingelheim, CeraVe, Galderma, Genesis Pharma, Incyte Corporation, La Roche-Posay, L’Oréal, Merck/MSD, Novartis, Pfizer and Takeda; is the representative for clinical trials of the Research Subcommittee of the Executive Committee of the British Association of Dermatologists (BAD); is a West Midlands BAD Representative (trustee of the BAD); has held a position of interest for the Trial Generation and Prioritisation Panel (UK Dermatology Clinical Trials Network); and is the NIHR West Midlands RRDN Dermatology Specialty Lead. S.R.D. has received fees and/or honoraria as a consultant for Almirall, Avita, Bristol Myers Squibb, Cassiopea SpA, Dermavant Sciences, Dermira, Ferndale Laboratories, Foamix, Galderma Laboratories LP, Incyte Corporation, MC2 Therapeutics, Ortho Dermatologics, Pfizer, Scientis, Sente Labs, SkinCeuticals LLC, UCB and Verrica Pharmaceuticals; has received stock options as a consultant for Gore Range Capital; has received honoraria as a speaker for Almirall and Ortho Dermatologics; has received grants or research funding as an investigator for AbbVie, AOBiome LLC, Atacama Therapeutics, Brickell Biotech, Dermavant Sciences, Incyte Corporation, Novan and SkinMedica; has served as an advisory board member for the Foundation for Research & Education of Dermatology; is a stockholder of Gore Range Capital; and is a shareholder in PDP of Texas. T.P. has received grants and/or honoraria from AbbVie, Aclaris Therapeutics, ACM Pharma, Almirall, Amgen, Astellas, Beiersdorf, Bristol Myers Squibb, Calypso, Celgene, Eli Lilly, First Tracks Biotherapeutics, Galderma, Genzyme, GSK, Incyte Corporation, ISIS Pharma, Janssen, La Roche-Posay, LEO Pharma, Novartis, Pfizer, Pierre Fabre, Priovant Therapeutics, Roivant, Sanofi, Sun Pharmaceuticals, SVR, Takeda UCB, and Vyne Therapeutics; is the cofounder of NIKAIA Pharmaceuticals; is the founder of SUNLUTION; and has patents on WNT agonists and GSK3β antagonists for repigmentation of vitiligo and on the use of CXCR3B blockers in vitiligo. J.R. has served as an advisor, consultant and/or speaker for AbbVie, Amgen, Apogee, Arcutis, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Galderma, Incyte Corporation, Janssen, LEO Pharma, L’Oréal, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma and UCB and served as an investigator for AbbVie, Alumis, Amgen, Apogee, Aristea, ASLAN, Bristol Myers Squibb, Celgene, Concert Pharmaceuticals, Dice Therapeutics, Eli Lilly, Incyte Corporation, Innovaderm, Janssen, Kymera, Kyowa Kirin, LEO Pharma, Merck, Novartis, Oruka, Pfizer, Sanofi Genzyme, Sun Pharma, Takeda and UCB. N.v.G. received grants and/or is a consultant and/or investigator for AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, First Tracks Biotherapeutics, Idorsia, Incyte Corporation, Merck/MSD, Novartis, Pfizer, Takeda and Teva and is chair of the Vitiligo Task Force for the European Academy of Dermatology and Venereology. A.W. has served as consultant and/or investigator for AbbVie, Incyte Corporation, Merck/MSD, Novartis, Pfizer, Philips and UCB; has received equipment from Humeca and PerfAction; and has served on advisory boards for AbbVie and Incyte Corporation. C.L. has served as a speaker or consultant or advisor or investigator or received honoraria from AbbVie, Altius, Amgen, Aralez, Arcutis, Bausch Health, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Cipher, Dermavant, Devonian, Eli Lilly, Fresenius Kabi, Galderma, GSK, Innovaderm, Intega Skin, Janssen, Kyowa Kirin, La Roche-Posay, LEO Pharma, L’Oréal, Medexus, MedX, Merck, Novartis, P&G, Pediapharm, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sandoz, Sentrex, TEVA, Tribute, UCB, Valeant, Viatris and Volo Health. M.A. reports consulting fees and/or research grants from AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, GSK, Hexal, Janssen, LEO Pharma, Medac, Merck, MSD, Mundipharma, Novartis, Pfizer, Sandoz and UCB. J.L.L.-E. has served as a consultant, participated in clinical trials and/or received lecture fees from AbbVie, Almirall, Babé, Bioderma, Galderma, Incyte Corporation, Invasix, Isdin, Janssen, LEO Pharma, Lilly, Novartis, Pierre Fabre and UCB. P.G. has served as a consultant for Aclaris Therapeutics, Clarify Medical, DermaForce, Incyte Corporation, Proctor & Gamble and Versicolor Technologies and as a principal investigator for Aclaris Therapeutics, Allergan/SkinMedica, Clinuvel Pharmaceuticals, Incyte Corporation, Johnson & Johnson, L’Oréal, Merz Pharma, Pfizer, Thync Global Inc. and VT Cosmetics. D.R. has served as a consultant, speaker or investigator for AbbVie, Abcuro, Almirall, AltruBio, Amgen, Arena, Astria, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Concert, CSL Behring, Dermavant Sciences, Dermira, Dualitas, EMD Serono, Galderma, Incyte Corporation, Janssen, Kymera, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT Therapeutics, Recludix, Regeneron Pharmaceuticals, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, Viela Bio and Zura Bio. K.B., S.W., S.K. and D.K. are employees and shareholders of Incyte Corporation. A.G.P. has served as an investigator for Avita, Clinuvel and Incyte Corporation; has served as a consultant for AbbVie, Avita, Boehringer Ingelheim, Incyte Corporation, Lilly, Pfizer, Sun Pharma, Thalocan, Villaris, Vimela, Vyne and WCG; and is a shareholder of Tara Medical.

Peer review

Peer review information

Nature Medicine thanks Jung Min Bae, Brian Kim, Caroline Le Poole and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editors: Liam Messin and Saheli Sadanand, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Table 1 Secondary efficacy outcomes during the 52-week placebo-controlled period

Full size table

Extended Data Table 2 Serious TEAEs during the 52-week placebo- controlled period

Full size table

Extended Data Table 3 Sensitivity and supplementary analyses of the primary endpoint

Full size table

Extended Data Fig. 1 STOP-V study design.

F-BSA, facial body surface area; F-VASI, facial Vitiligo Area Scoring Index; F-VASI75, ≥75% improvement from baseline in F-VASI; NSV, nonsegmental vitiligo QD, once daily; T-BSA, total body surface area; T-VASI, total Vitiligo Area Scoring Index; T-VASI50/T-VASI75, ≥50%/≥75% improvement from baseline in T-VASI; VNS, Vitiligo Noticeability Scale. a As assessed by the investigator. b Randomization was stratified by F-VASI (<1.5 and ≥1.5), T-VASI (4–20 and >20), and Fitzpatrick skin type (I–II and III–VI).

Extended Data Fig. 2 Achievement of F-VASI50 and F-VASI90 in STOP-V1 and STOP-V2.

F-VASI50/F-VASI90, ≥50%/≥90% improvement from baseline in facial Vitiligo Area Scoring Index. The percentage of patients achieving (a) F-VASI50 and (b) F-VASI90 at each visit are presented as observed, with error bars representing the 95% CI and n values indicating the number of patients with available data at each time point.

Extended Data Fig. 3 Blood CPK by visit in STOP-V1 and STOP- V2.

CPK, creatine phosphokinase. IQR, interquartile range; Q1, quartile 1; Q3, quartile 3. Data are presented as observed and summarized descriptively, with n values indicating the number of patients with available data at each time point. IQR, represented by boxes (with box bounds indicating the 25th and 75th percentiles); medians (centers), by black lines; means, by diamonds; outliers, by circles; Q1–(1.5 × IQR) and Q3 + (1.5 × IQR), by whiskers.

Extended Data Fig. 4 ALT and AST by visit in STOP-V1 and STOP-V2.

ALT, alanine aminotransferase; AST, aspartate aminotransferase. IQR, interquartile range; Q1, quartile 1; Q3, quartile 3. (a) ALT and (b) AST data are presented as observed and summarized descriptively, with n values indicating the number of patients with available data at each time point. IQR, represented by boxes (with box bounds indicating the 25th and 75th percentiles); medians (centers), by black lines; means, by diamonds; outliers, by circles; Q1–(1.5 × IQR) and Q3 + (1.5 × IQR), by whiskers. One outlier patient in the placebo group in STOP-V2 is not shown. This patient had elevated ALT (621 U/L) and AST (627 U/L) levels at Week 8 with normal levels at Week 4 (19 and 15 U/L, respectively) and slightly elevated or normal levels at an unscheduled visit after Week 8 (109 and 21 U/L).

Extended Data Fig. 5 Hemoglobin and platelets by visit in STOP-V1 and STOP-V2.

IQR, interquartile range; Q1, quartile 1; Q3, quartile 3. (a) Hemoglobin and (b) platelet data are presented as observed and summarized descriptively, with n values indicating the number of patients with available data at each time point. IQR, represented by boxes (with box bounds indicating the 25th and 75th percentiles); medians (centers), by black lines; means, by diamonds; outliers, by circles; Q1–(1.5 × IQR) and Q3 + (1.5 × IQR), by whiskers.

Extended Data Fig. 6 Percentage change from baseline in F- VASI in STOP-V1 and STOP-V2.

F-VASI, facial Vitiligo Area Scoring Index. The mean percentage change from baseline in F-VASI at each visit is presented as observed, with error bars representing the 95% CI and n values indicating the number of patients with available data at each time point. Baseline mean (95% CI) F-VASI was 1.04 (0.97–1.12) for the povorcitinib group and 1.06 (0.98–1.14) for placebo in STOP-V1 and 1.16 (1.06–1.26) for the povorcitinib group and 1.18 (1.09–1.27) for placebo in STOP-V2.

Extended Data Fig. 7 F-VASI75 response rates differences and odds ratios at Week 52 by subgroup in STOP V1 and STOP-V2.

F-BSA, facial body surface area; F-VASI, facial Vitiligo Area Scoring Index; F-VASI75, ≥75% improvement from baseline in F-VASI; NE, not evaluable; T-BSA, total body surface area; T-VASI, total Vitiligo Area Scoring Index. For each subgroup, as-observed F-VASI75 response rates at Week 52 and corresponding n values (the number of patients with available data at each time point) are listed for the povorcitinib and placebo groups. The response rate differences ± SE between povorcitinib and placebo are presented in the plot and listed numerically. The odds ratios and corresponding 95% CI for povorcitinib versus placebo are also listed.

Rights and permissions

This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ezzedine, K., Lui, H., Eleftheriadou, V. et al. Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials. Nat Med (2026). https://doi.org/10.1038/s41591-026-04739-2

Download citation

  • Received: 14 August 2026

  • Accepted: 05 October 2026

  • Published: 02 November 2026

  • Version of record: 02 November 2026

  • DOI: https://doi.org/10.1038/s41591-026-04739-2

来源:Nature Medicine · nature.com